Etretinate is a second-generation retinoid that was used as an active pharmaceutical ingredient in medications for severe psoriasis. It was developed by Hoffmann–La Roche and approved by the FDA in 1986, but later withdrawn from several markets due to a high risk of birth defects.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Restricted or banned substances
Substances on this list are banned or restricted under the named regulation. This page is a compliance reference — verify your obligations under applicable law.
CAS 54350-48-0
Butyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
pharmaceutical intermediate
Butyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
pharmaceutical intermediate
Acitretin Impurity 10
pharmaceutical intermediate
(R)-Tetrahydropapaverine hydrochloride
pharmaceutical raw material
Phosphoric acid triethylene imide
pharmaceutical raw material
Theofibrate
pharmaceutical raw material
Aminolevulinic acid hydrochloride
pharmaceutical raw material
The international HS code for Etretinate (CAS 54350-48-0) is 2918.99.
2918.99
2918 99 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
HQMNCQVAMBCHCO-DJRRULDNSA-N
CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C